Harvard Medical School/Harvard School of Dental Medicine
`Format for the Curriculum Vitae
`
`
`
`Date Prepared: April 30, 2015
`Name:
`Randall Mark Zusman, MD
`Office Address: Massachusetts General Hospital, Yawkey Center for Outpatient Care,
`Suite 5B-5800, Boston, MA 02114
`99 Needham Street, #1310, Newton, MA 02461
`617-7267790
`rzusman@partners.org
`617-7267766
`Detroit, Michigan
`
`Home Address:
`Work Phone:
`Work Email:
`Work FAX:
`Place of Birth:
`
`Education
`1969
`
`B.S. Chemistry with
`Highest Honors, Phi
`Beta Kappa
`M.D.
`
`Chemistry
`
`Medicine
`
`
`
`
`
`
`1973
`
`University of Michigan,
`Ann Arbor, Michigan
`
`Yale University School of
`Medicine, New Haven,
`CT
`
`
`Massachusetts General
`Hospital, Boston, MA
`Massachusetts General
`Hospital, Boston, MA
`Harvard Medical School,
`Boston, MA
`National Heart, Lung and
`Blood Institute,
`Hypertension-Endocrine
`Branch, National
`Institutes of Health,
`Bethesda, MD
`
`Board Certifications
`
`1976 American Board of Internal Medicine - Internal Medicine
`
`1983 American Board of Internal Medicine - Cardiovascular Diseases
`
`Postdoctoral Training
`7/73-6/74
`Intern
`
`Medicine
`
`Medicine
`
`Medicine
`
`
`
`7/74-6/75
`
`Junior Assistant
`Resident
`7/73-6/75 Clinical Fellow
`
`
`
`7/75-6/77
`
`Clinical Associate
`
`Hypertension/Endocrinology,
`Cardiology
`
`1
`
`
`
`CFAD Ex. 1027 (1 of 31)
`
`

`
`Massachusetts General
`Hospital, Boston, MA
`Massachusetts General
`Hospital, Boston, MA
`Harvard Medical School,
`Boston, MA
`Massachusetts General
`Hospital, Boston, MA
`Harvard Medical School,
`Boston, MA
`
`Harvard Medical School,
`Boston, MA
`Harvard Medical School,
`Boston, MA
`Harvard Medical School,
`Boston, MA
`
`Massachusetts General
`Hospital, Boston, MA
`Massachusetts Eye and
`Ear Infirmary, Boston,
`MA
`Massachusetts General
`Hospital, Boston, MA
`Massachusetts General
`Hospital, Boston, MA
`Massachusetts General
`Hospital, Boston, MA
`Medical Department,
`Massachusetts Institute
`of Technology,
`Cambridge, MA
`
`
`
`7/77-12/77
`
`Senior Assistant
`Resident
`1/78-12/78 Chief Resident in
`Medicine
`7/77-12/78 Clinical Fellow
`
`Medicine
`
`Medicine
`
`Medicine
`
`1/79-6/80
`
`1/79-6/80
`
`Clinical and Research
`Fellow
`Research Fellow
`
`Cardiology
`
`Cardiology
`
`Medicine
`
`Medicine
`
`
`Faculty Academic Appointments
`
`1/78-6/80
`Instructor
`
`7/80- 12/93 Assistant Professor
`
`
`
`1/94 -
`
`Associate Professor
`
`Medicine
`
`
`Appointments at Hospitals/Affiliated Institutions
`7/80– 12/84 Assistant
`Medicine
`
`
`
`7/80-6/83
`
`Consultant
`
`Medicine
`
`
`
`1/85-12/88 Assistant Physician
`
`Medicine
`
`1/89-12/08 Associate Physician
`
`Medicine
`
`1/09 -
`
`7/01 -
`
`Physician
`
`Consultant
`
`Medicine
`
`Cardiology
`
`Hypertension Clinic, Cardiac Unit,
`Massachusetts General Hospital, Boston,
`MA
`Hypertension Division, Cardiac Unit,
`Massachusetts General Hospital, Boston,
`MA
`
`
`2
`
`
`
`
`Major Administrative Leadership Positions
`Local
`1981-83
`
`Director
`
`
`
`1982-89
`
`Director
`
`CFAD Ex. 1027 (2 of 31)
`
`

`
`
`
`1983-89
`
`Director
`
`1982-
`
`Director
`
`1992-99
`
`Director
`
`
`
`
`Committee Service
`Local
`1978-
`
`
`
`
`1979-83
`
`
`
`1982-1986
`
`Internship Selection Committee
` 2008-9 Subcommittee Co-Chairman
` 2010- Subcommittee Chairman
`Subcommittee for the Review of
`Research Proposals
`Scientific Advisory Committee
`
`2009-
`
`Scientific Advisory Committee
`
`
`
`Professional Societies
`1973-1991 American Federation for Clinical
`Research
`1981-1990
`1982
`1983-1986
`1989-1990
`
`
`
`1976-
`1978-
`1988-
`
`American Society of Nephrology
`American Heart Association
`American Society of Hypertension
`1999-
`
`2009-
`
`Hypertension Associates, Cardiac Unit,
`Massachusetts General Hospital, Boston,
`MA
`Hypertension Section, Cardiac Division,
`Medical Services, Massachusetts General
`Hospital, Boston, MA
`Cardiac Rehabilitation Program,
`Spaulding Rehabilitation Hospital,
`Boston, MA
`
`Medical Services, Massachusetts General
`Hospital
`
`Committee on Research, Massachusetts
`General Hospital
`General Clinical Research Center,
`Massachusetts General Hospital
`Office of Research and Career
`Development, Massachusetts General
`Hospital
`
`
`
`Member, Public Policy Committee
`Co-Chairman, Public Policy Committee
`Chairman, Public Policy Committee
`Chairman, 50th Anniversary Membership
`Campaign
`Member
`Member
`Member
` Clinical Specialist in Hypertension
`(Inaugural Designee)
` Association of Hypertension Specialists
`(Inaugural Designee)
`Fellow
`
`American College of Cardiology
`
`1990-
`
`Editorial Activities
`Ad hoc Reviewer:
`
`
`New England Journal of Medicine, Circulation, Journal of Clinical
`Investigation, Hypertension, American Journal of Hypertension, Journal
`of the American College of Cardiology, American Journal of Cardiology,
`Journal of the American Society of Hypertension, Circulation Research,
`3
`
`
`
`CFAD Ex. 1027 (3 of 31)
`
`

`
`
`
`
`
`
`
`
`2009-
`
`Editorial Review Board, Journal of Applied Research
`in Clinical and Experimental Therapeutics
`
` 2015 - Advisory Board, Cardiology and Therapy
`
`
`
`Honors and Prizes
`
`
`1966
`
`
`
`Phi Eta Sigma
`
`1968
`
`
`
`Phi Lambda Upsilon
`
`4
`
`
`
`American Journal of Medicine, Kidney International, Journal of
`Complementary and Alternative Medicine,
`American Journal of Physiology
`
`Editorial Boards:
`
`
`1981-1984 Associate Editor, Prostaglandins, Section on Clinical
`Pharmacology
`
`
`1981-1983 Associate Editor, Clinical Research, American Federation
`for Clinical Research
`
`
`1983-1988 Associate Editor, Hypertension
`
`Editor-elect, Clinical Research, American Federation for
`Clinical Research
`
`Editor, Clinical Research, American Federation for Clinical
`Research
`
`Editorial Board, Journal of Clinical Hypertension
`
`Editorial Board, Journal of Hypertension
`
`1983-1984
`
`
`1984-1989
`
`
`1985-1987
`
`1990-1993
`
`
`
`1999-2004
`
`1996– 2001 Editorial Advisory Board, Reviews in Contemporary
`Pharmacotherapy
`
`Editorial Board, Preventive Cardiology Clinic, Cardiology
`Review
`
`Editorial Advisory Board, Managed Care
`
`
`2001-2006
`
`2002- Contributing Guest Editor-Health and Medicine;
`ABC.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`CFAD Ex. 1027 (4 of 31)
`
`

`
`1969
`
`1972
`
`1973
`
`
`
`
`
`
`
`
`
`Phi Beta Kappa
`
`Alpha Omega Alpha
`
`Louis B. Nahum Prize for Cardiovascular Research,
` Yale University School of Medicine
`
`1974 Sigma Xi
`
`1980-1985
`
`1999
`
`Established Investigator, American Heart Association
`
`Specialist in Clinical Hypertension, American Society of Hypertension
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Report of Funded and Unfunded Projects
`
`Funding Information
`Past
`
`#EFC555
`Site Investigator Sanofi-Aventis
`ATHENA: A placebo-controlled, double-blind parallel Trial to assess the efficacy of
`Dronedarone for the prevention of cardiovascular hospitalization or death from any
`cause in patients with atrial fibrillation/atrial flutter.
`
`This study established the safety of Dronedarone in patients with atrial fibrillation
`and the reduction in death, hospitalization and recurrent atrial fibrillation in this
`high risk patient population.
`
`Site Investigator
`
`Pfizer Pharmaceuticals
`
`A Phase 3, Open-label, multi-center, randomized, parallel group study of the efficacy
`and safety of the fixed combination torcetrapib/atorvastatin administered once daily
`compared to fixed combination ezetimide./simvastatin for 6 weeks in subjects with
`Dyslipidemia.
`
`This study established the marked lipid lowering efficacy of torcetrapib (a CETP
`inhibitor) and atorvastatin in patients with hypercholesterolemia. It also provided
`information regarding the blood pressure raising properties of torcetrapib which led
`to the discontinuation of study of this once-promising pharmaceutical product.
`
`Site Investigator
`
`
`
`Astra Zeneca
`
`#4522US/0011
`
`JUPITER: A randomized double-blind placebo-controlled multicenter Phase III
`study of rosuvastatin (Crestor) 20 mg in the primary prevention of cardiovascular
`events among subjects with low levels of LDL-cholesterol and elevated levels of c-
`reactive protein.
`
`
`5
`
`
`
`CFAD Ex. 1027 (5 of 31)
`
`

`
`This study established the critically important principal of treating patients with an
`elevated hs-CRP but a normal LDL cholesterol with the lipid-lowering agent
`rosuvastatin so as to reduce cardiovascular risk. This study has established a new
`standard of care for this patient population and will be applicable to millions of
`persons world-wide.
`
`Site Investigator
`
`
`
`Pfizer Pharmaceuticals
`
`#A3191172
`
`PRECISION: Prospective, randomized evaluation of Celecoxib Integrated Safety vs.
`Ibuprofen or Naproxen – A randomized double blind parallel group study of CV
`safety in osteo or rheumatoid arthritis patients with or at high risk for cardiovascular
`disease comparing celecoxib with naproxen and ibuprofen.
`
`This study is designed to determine the relative safety and efficacy of three
`independent treatment strategies in patients at high risk of cardiovascular events who
`require treatment of osteo or rheumatoid arthritis.
`
`Site Investigator
`
`
`
`
`Novartis Pharmaceuticals
`
`VALUE: Outcomes in hypertensive patients at high cardiovascular risk treated with
`valsartan or amlodipine based regimens: a randomized trial
`
`This study established as a standard of care principle the importance of rapid blood
`pressure control, with either a dihydropyridine calcium antagonist, or an angiotensin
`receptor blocker, to reduce cardiovascular mortality in a high risk hypertensive
`patient population.
`
`Site Investigator
`
`
`
`G.D. Searle Pharmaceuticals
`
`Double-blind, Controlled, randomized comparison study of the efficacy and safety of
`eplerenone and enalapril alone and in combination with each other in patients with
`left ventricular hypertrophy and essential hypertension.
`
`This study established the efficacy of eplerenone, a highly specific aldosterone
`antagonist, as an alternative strategy to enalapril, an angiotensin converting enzyme
`inhibitor, in patients with hypertension and associated left ventricular hypertrophy.
`
`Site Investigator
`
`
`
`CARE: Cholesterol and Recurrent Events
`
`Bristol Myers Squibb
`
`
`
`This study established the standard of care principle for the use of statin therapy in
`patients who have survived a myocardial infarction and have mild
`hypercholesterolemia.
`
`Site Investigator
`
`
`
`SmithKline Beecham Pharmaceuticals BRL049653/048
`
`6
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`CFAD Ex. 1027 (6 of 31)
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Current
`
`
`
`
`2008-
`
`
`
`
`
`
`
`A randomized, double-blind study to compare the durability of glucose lowering and
`preservation of pancreatic beta-cell function of Rosiglitazone Monotherapy compared
`to Metformin or glyburide/glibenclamide in Patients with drug-naïve, recently
`diagnosed type 2 diabetes mellitus (ADOPT – A Diabetes Outcome Progression Trial)
`
`This study provided standard of care establishing data for the initial use of
`Metformin as a therapeutic strategy in patients with newly diagnosed diabetes
`mellitus. It also contributed to the data base which ultimately led to the withdrawal
`of Rosiglitazone from the marketplace due to increased cardiovascular mortality and
`morbidity associated with its use.
`
`
`Site Investigator
`
`E. R. Squibb and Company
`
`SAVE: Survival and Ventricular Enlargement
`
`This study established the standard of care principle of the use of angiotensin
`converting enzyme inhibitor therapy in patients who have survived a myocardial
`infarction and have a depressed left ventricular ejection fraction.
`
`
`
`
`
`
`
`National Center for Complementary and Alternative
`Co-Investigator
`Medicine/National Institutes of Health #1R21AT003315-01A2
`
`Mechanisms of the Relaxation Response in Elderly Hypertensives
`
`The major goal of this project is to assess whether nitric oxide is the
`underlying biological mechanism for the reduction in blood pressure in
`systolic hypertenison treated with relaxation response therapy in the absence
`of pharmacologic intervention.
`
`
`
`
`Report of Local Teaching and Training
`Teaching of Students in Courses
`2007-
`HST 350 Pharmacology and Clinical
`
`Therapeutics –Guest Lecturer – one 3-
`
`hour lecture/yr, Topic: Evaluation and
`Treatment of Patients with
`Hypertension; 50 -75 Fourth year
`HMS/HST students
`Cardiology Fellowship Core Curriculum,
`Lecturer, Topic: Evaluation and
`
`
`
`
`
`
`
`2009-
`
`
`
`
`
`Harvard Medical School, Boston, MA
`and Massachusetts Institute of
`Technology Health Science and
`Technology Curriculum, Cambridge, MA
`
`Cardiology Division, Medical Services,
`Massachusetts General Hospital, Boston,
`
`7
`
`
`
`CFAD Ex. 1027 (7 of 31)
`
`

`
`Treatment of Patients with
`Hypertension; 20 -30 Cardiac fellows,
`residents, students and nurse
`practitioners; one 1-hour lecture per year
`
`MA
`
`
`
`
`
`
`
`Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs)
`Cardiology Division, Medical Services,
`1980-
`Attending Physician
`
`Massachusetts General Hospital, Boston,
` Cardiac Consultation Service (2
`
`MA
`weeks/year: 2 fellows, 2 – 4 residents, and
`2 - 4 students)
` Cardiac Step-Down Unit Service (2
`weeks/year: 2 fellows, 6 residents)
` Cardiac Outpatient Service ( Four 4-
`hour sessions/year: 8 – 12
`fellows/residents)
`
`
`
`Formal Teaching of Peers (e.g., CME and other continuing education courses)
`
`
`
`
`
`
`
`
`1980 -
`
`Harvard Medical School Continuing Medical Education Courses for
`physicians, Boston, MA. One lecture per course on the “Treatment and
`Evaluation of Patients with Hypertension”
`-presented in review courses in Internal Medicine, Vascular Medicine,
`Vascular Surgery, and Emergency Medicine – 1 – 4 presentations/year.
`
`2006 – 2012 Practicing Clinicians Exchange –continuing medical education
`
`
`Course for nurse practitioners and physician assistants. One
`
`
`lecture per course on “Atherothrombotic Vascular Disease” –
` 6 courses/year – various locations in the United States.
`
`
`
`
`
`
`
`
`2006 - 2012 Primary Care Education (PRIMED) – continuing medical
`
`
`
`Education course for physicians. One lecture per course on
`
`
`
`“Antiplatelet Therapy and the Treatment of Atherothrombotic
`
`
`
`Vascular disease” – 6 course per year – various locations in the
`
`
`
`United States.
`
`Report of Clinical Activities and Innovations
`Current Licensure and Certification
` 1975-
`Massachusetts License Registration No. 37456
`1976
`District of Columbia Registration
`
`1988
`Maryland License Registration No. D47367
`1976 -
`American Board of Internal Medicine, Internal Medicine
`1983 -
`American Board of Internal Medicine, Cardiovascular Diseases
`
`
`
`8
`
`
`
`CFAD Ex. 1027 (8 of 31)
`
`

`
`
`
`
`Practice Activities
`
`1980 - Cardiology Clinical Practice Massachusetts General Hospital,
`Cardiology Division, Section on Hypertension and Vascular Medicine, Yawkey
`Center for Outpatient Care, 55 Fruit Street, Boston, MA
`
`
`
`2001- Cardiology Consultation Practice, Massachusetts Institute of
` Technology, Medical Department, E23- 2nd floor,
` 77 Massachusetts Avenue, Cambridge, MA
`
`
`
`Report of Technological and Other Scientific Innovations
`Renin Inhibitory Peptide –
`
`In collaboration with Dr. Edgar Haber, James Burton, and William Carlson and with the support
`of the National Aeronautics and Space Administration, we developed a peptide with renin
`inhibitory properties. This substance, available in exceedingly small quantities, was then used to
`study the physiology of the renin angiotensin system, the regulation of blood pressure, and the
`effects of weightlessness (in gravity-free environments) on cardiac and renal physiology. Our work
`provided the basis for the ultimate development of aliskiren, a recently FDA-approved, orally active
`renin inhibitor, which is now in use for the treatment of hypertension and being tested for the
`treatment of congestive heart failure, asymptomatic LV dysfunction, and diabetic nephropathy.
`
`Citations:
`
`Zusman RM, Burton J, Christensen D, Nussberger J, Dodds A, Haber E. Hemodynamic
`effects of a competitive renin inhibitory peptide in humans: Evidence for multiple
`mechanisms of action. Trans Assoc Am Phys 1983; XCVI:365-374.
`
`Zusman RM, Hui K, Nussberger J, Christensen DM, Higgins J, Carlson WD, Schoenfeld D,
`Haber E. R-PEP-27, a potent inhibitor, decreases plasma angiotensin II and blood pressure
`in normal volunteers. Am J Hypertension 1984; 7:295-301.
`
`
`
`
`
`Report of Education of Patients and Service to the Community
`Activities
`
`
`1980 -
`
`Consultant/Guest commentator - ABC News, CBS News, NBC News, FOX
`News, ABC Evening News, CNN News, and National Public Radio
`
`
`
`Frequent guest commentator/consultant for on-air stories about health reports on
`cardiology, hypertension, cardiac risk reduction, stress, etc. Recent contributions
`include discussions of cardiac risk factors and cardiac risk reduction (CNN News –
`9
`
`
`
`CFAD Ex. 1027 (9 of 31)
`
`

`
`prompted by the tragic death of Tim Russert, the effects of stress and the economic
`downturn on cardiovascular health and specifically blood pressure control (FOX
`News, NBC News), and the role of life-style modification, salt restriction and the
`relaxation response for the control of hypertension (National Public Radio).
`
`
`
`
`
`
`
`Educational Material for Patients and the Lay Community
`
`Books, monographs, articles and presentations in other media
`
`
`1. Zusman RM (Consultant Editor). High Blood Pressure: A Special Report from the
`Harvard Health Letter. 2001; Harvard Medical School Health Publications Group, Boston,
`MA.
`
`Citation
`2009-
`1997-2000 Citation
`
`2009
`
`
`
`
`
`
`
`
`
`
`
`
`
`Who’s Who in America
`Who’s Who in the East
`
`Nominee – Brian McGovern Award for Clinical Excellence - Massachusetts General
`Hospital Physicians Organization
`
`10
`
`
`
`
`2.
`
`
`
`3.
`
`
`
`4.
`
`
`
`5.
`
`
`
`6.
`
`Zusman RM (Consultant Editor). High Blood Pressure: A Special Report from the
`Harvard Health Letter. 2004; Harvard Medical School Health Publications Group, Boston,
`MA.
`
`Zusman, RM (Medical Editor). Hypertension: Controlling the ‘silent killer’. A Special
`Health Report from the Harvard Medical School. 2007; Harvard Health Publications
`Group, Boston, MA.
`
`Zusman, RM (Contributor) In Body Signs by Joan Liebmann-Smith, Ph.D. and Jacqueline
`Nardi Egan, 2007, Bantam Dell Books, New York, NY.
`
`Zusman, RM (Medical Editor). Hypertension: Controlling the ‘silent killer’. A Special
`Health Report from the Harvard Medical School. 2009; Harvard Health Publications
`Group, Boston, MA.
`
`Zusman, RM (Medical Editor). Hypertension: Controlling the ‘silent killer’. A Special
`Health Report from the Harvard Medical School. 2011; Harvard Health Publications
`Group, Boston, MA.
`
`
`
`America’s Top Doctors for Men
`
`
`
`Men’s Health Magazine
`
`Boston Magazine
`
`
`Recognition
`
`2007
`
`2008, 2009, 2010, 2011, 2012, 2013 Boston’s Top Docs
`
`
`
`CFAD Ex. 1027 (10 of 31)
`
`

`
`
`
`Boston Super Doctors (superdoctors.com)
`
`
`2011
`
`2011, 2012 Top Doctors – U.S. News and World Report
`2014
`America’s Top Physicians (Showmark)
`
`
`
`
`
`
`Report of Scholarship
`Publications
`
`Peer reviewed publications in print or other media
`
`
`
`
`Original Reports:
`
`1.
`
`Zusman RM. Quantitative conversion of prostaglandin A or prostaglandin E to
`prostaglandin B. Prostaglandins 1972; 1:167-168.
`
`Zusman RM, Caldwell BV, Speroff L, Behrman H. Radioimmunoassay of the A
`prostaglandins. Prostaglandins 1972; 2:41-53.
`
`Zusman RM, Forman B, Schneider G, Caldwell BV, Speroff L, Mulrow PJ. The effect of
`chronic sodium loading and sodium restriction on plasma and renal concentrations of
`prostaglandin A in normal Wistar and spontaneously hypertensive Aoki rats. Clin Sci Mol
`Med 1973; 45(Suppl. 1): 325S-329S.
`
`Zusman RM, Spector D, Caldwell BV, Speroff L, Schneider G, Mulrow PJ. The effect of
`chronic sodium loading and sodium restriction on plasma prostaglandin A, E, and F
`concentrations in normal humans. J Clin Invest 1973; 52:1093-1098.
`
`Spector D, Zusman RM, Caldwell BV, Speroff L. The distribution of prostaglandins A, E,
`and F in the human kidney. Prostaglandins 1974; 6:263-270.
`
`Auletta FJ, Zusman RM, Caldwell BV. Development and standardization of a
`radioimmunioassay for prostaglandins E, F and A. Clin Chem 1974; 20:1580-1587.
`
`Axelrod L, Trzepacz PT, Zusman RM, Martin DB. Antilipolytic effect of prostaglandin E2
`analogues: Therapeutic implications. Life Sci 1976; 18:627-632.
`
`Zusman RM, Axelrod L, Tolkoff-Rubin N. The treatment of hepatorenal syndrome with
`intra-renal administration of prostaglandin E1. Prostaglandins 1977; 13:812-830.
`
`Zusman RM, Keiser HR. Prostaglandin biosynthesis by rabbit renomedullary interstitial
`cells in tissue culture: Stimulation by angiotensin II, bradykinin and arginine vasopressin. J
`Clin Invest 1977; 60:215-223.
`
`11
`
`
`
`
`2.
`
`
`
`3.
`
`
`4.
`
`
`5.
`
`
`6.
`
`
`7.
`
`
`8.
`
`
`9.
`
`CFAD Ex. 1027 (11 of 31)
`
`

`
`
`
`
`10. Zusman RM, Keiser HR. Prostaglandin E2 biosynthesis by rabbit renomedullary interstitial
`cells in tissue culture: Mechanism of stimulation by angiotensin II, bradykinin, and arginine
`vasopressin. J Biol Chem 1977; 252:2069-2071.
`
`
`11. Zusman RM, Keiser HR, Handler JS. Vasopressin-stimulated prostaglandin E biosynthesis
`in the toad urinary bladder: Effect on water flow. J Clin Invest 1977; 60:1339-1347.
`
`
`12. Zusman RM, Keiser HR, Handler JS. Inhibition of vasopressin-stimulated prostaglandin E
`biosynthesis by chlorpropamide in the toad urinary bladder: Mechanism of enhancement of
`vasopressin-stimulated water flow. J Clin Invest 1977; 60:1348-1353.
`
`
`13. Zusman RM, Keiser HR, Handler JS. A hypothesis for the molecular mechanism of action
`of chlorpropamide in the treatment of diabetes mellitus and diabetes insipidus. Fed Proc
`1977; 36:2728-2729.
`
`
`14. Zusman RM, Keiser HR, Handler JS. Effect of adrenal steroids on vasopressin-stimulated
`PGE synthesis and water flow. Am J Physiol 1978; 234:F532-F540.
`
`
`15. Vinci JM, Gill JR, Jr., Bowden RE, Pisano JJ, Izzo JL, Jr., Radfar N, Taylor AA, Zusman
`RM, Bartter FC, Keiser HR. The kallikrein-kinin system in Bartter’s syndrome and its
`response to prostaglandin synthetase inhibition. J Clin Invest 1978; 61:1671-1682.
`
`
`
`16. Orloff J, Zusman RM. Role of prostaglandin E (PGE) in the modulation of the action of
`vasopressin on water flow in the urinary bladder of the toad and mammalian kidney. J
`Membrane Biol 1978; 40:297-304.
`
`
`17. Zusman RM, Vinci JM, Bowden RE, Horwitz D, Keiser HR. Effect of indomethacin and
`adrenocorticotrophic hormone on renal function in man: An experimental model of
`inappropriate antidiuresis. Kid Internat 1979; 15:62-70.
`
`
`18. Vinci JM, Zusman RM, Izzo JL, Jr., Bowden RE, Horwitz D, Pisano JJ, Keiser HR. Human
`urinary and plasma kinins: Relationship to sodium-retaining steroids and plasma renin
`activity. Circ Res 1979; 44:228-237.
`
`
`19. Vinci JM,. Horwitz D, Zusman RM, Pisano JJ, Catt KJ, Keiser HR. The effect of converting
`enzyme inhibition with SQ20,881 on plasma and urinary kinins, prostaglandin E, and
`angiotensin II in hypertensive man. Hypertension 1979; 1:416-426.
`
`
`20. Brown CA, Zusman RM, Haber E. Characterization of an angiotensin-binding site in
`rabbit renomedullary interstitial cells in tissue culture: Correlation with prostaglandin
`biosynthesis. Trans Am Assoc Phys 1979; 92:169-174.
`
`
`21. Cagan LM, Zusman RM, Pisano JJ. Formation of la, 1b Dihomoprostaglandin E2 by rabbit
`renal interstitial cell cultures. Prostaglandins 1979; 18:617-621.
`
`
`22. Zusman RM, Keiser HR. Regulation of prostaglandin E2 synthesis by angiotensin II,
`12
`
`
`
`CFAD Ex. 1027 (12 of 31)
`
`

`
`
`
`potassium, osmolatity, and dexamethasone. Kid Internat 1980; 17:277-283.
`
`
`23. Zusman RM, Brown CA. Role of phospholipase in the regulation of prostaglandin E2
`biosynthesis by rabbit renomedullary interstitial cells in tissue culture: Effects of
`angiotensin II, potassium, hyperosmolality, dexamethasone, and protein synthesis inhibition.
`In: Advances in Prostaglandin and Thromboxane Research. 1980; 6:243-248.
`
`
`24. Brown CA, Zusman RM, Haber E. Identification of an angiotensin receptor in rabbit
`renomedullary interstitial cells in tissue culture: Correlation with prostaglandin
`biosynthesis. Circ Res 1980; 46:802-807.
`
`
`25. Zusman RM, Crow JW, Cato AE, Tolkoff-Rubin N. Effects of prostaglandin infusions in
`uremic patients: Hematologic and hemodynamic response. Clin Pharmacol Ther 1981;
`30:251-257.
`
`
`26. Zusman RM, Rubin RH, Cato AE, Cocchetto DM, Crow JW, Tolkoff-Rubin NE.
`Hemodialysis using prostacyclin instead of heparin as the sole antithrombotic agent. N Engl
`J Med 1981; 304:934-939.
`
`
`27. Doppelt SH, Slovik DM, Neer RM, Nolan J, Zusman RM, Potts JT, Jr. Gut mediated
`hypercalcemia in rabbits bearing the VX2 carcinoma: A new mechanism for tumor-induced
`hypercalcemia. Proc Natl Acad Sci USA 1982; 79:640-644.
`
`
`
`28. Khosla S, Kinter LB, Zusman RM, Beeuwkes R, III. ACTH and indomethacin-induced
`antidiuresis in low salt Brattleboro strain rats: Induction and escape. Annals New York
`Academy Science 1982; 394:265-269.
`
`
`29. Zusman RM, Burton J, Christensen D, Nussberger J, Dodds A, Haber E. Hemodynamic
`effects of a competitive renin inhibitory peptide in humans: Evidence for multiple
`mechanisms of action. Trans Assoc Am Phys 1983; XCVI:365-374.
`
`
`30. Ausiello DA, Zusman RM. The role of calcium in the stimulation of prostaglandin synthesis
`by vasopressin in rabbit renal-medullary interstitial cells in tissue culture. Biochem J 1984;
`220:139-145.
`
`
`31.
`
`Fulghum TG, DiMarco JP, Supple EW, Nash I, Gendlerman J, Eton DF, Newell JB, Zusman
`RM, Powell WJ, Jr. Effect of prostacyclin on vascular capacity in the dog. J Clin Invest
`1985; 76:999-1006.
`
`
`32. Zusman RM, Christensen DM, Kanarek DJ, Kiess MC, Boucher CA. Evaluation of bepridil
`for the treatment of angina pectoris: Evidence for preservation of left ventricular function.
`Am J Cardiol 1985; 55:30C-35C.
`
`
`
`33. Hill JA, O’Brien JT, Alpert JS, Gore JM, Zusman RM, Christensen D, Boucher CA,
`Vetrovec G, Borer JS, Friedman C, Mack R, Conti CR, Pepine CJ. Effect of bepridil in
`patients with chronic stable angina: Results of a multicenter trial. Circulation 1985; 71:98-
`103.
`
`13
`
`
`
`CFAD Ex. 1027 (13 of 31)
`
`

`
`
`
`
`34. Gold HK, Johns JA, Leinbach RC, Yasuda T, Grossbard E, Zusman RM, Collen D. A
`randomized double-blind, placebo-controlled trial of recombinant human tissue-type
`plasminogen activator (RT-PA) in patients with unstable angina pectoris. Circulation 1987;
`75:1192-1199.
`
`
`
`35. Zusman RM. Effects of converting enzyme inhibitors on the renin-angiotensin-aldosterone,
`bradykinin, and arachidonic acid-prostaglandin systems: Correlation of chemical structure
`and biologic activity. Am J Kid Dis 1987; 10:I-13-23.
`
`
`36. Miller DD, Ruddy TD, Zusman RM, Okada RD, Strauss HW, Kanarek DJ, Christensen D,
`Federman EB, Boucher CA. Left ventricular ejection fraction response to exercise in
`asymptomatic hypertension. Am J Cardiol 1987; 59:409-413.
`
`
`37. Dimsdale JE, Graham RM, Ziegler MG, Zusman RM, Berry CC. Age, race, diagnosis, and
`sodium effects on the pressor response to infused norepinephrine. Hypertension 1987;
`10:564-569.
`
`
`38. Zusman RM, Christensen DM, Federman EB, Ruddy TD, Miller DD, Boucher CA.
`Nifedipine, but not propranolol, improves left ventricular systolic and diastolic function in
`patients with hypertension. Am J Cardiol 1989; 64:51F-61F.
`
`
`39. Zusman RM, Christensen DM, Higgins J, Boucher CA. Nifedipine improves left ventricular
`function in patients with hypertension. J Cardiovascular Pharmacol 1991; 18:843-848.
`
`
`40. Zusman RM, Christensen DM, Higgins J, Boucher CA. Effects of fosinopril on cardiac
`function in patients with hypertension: Radionuclide assessment of left ventricular systolic
`and diastolic performance. Amer J Hypertension 1992; 5:219-223.
`
`
`41. Zusman RM, Christensen DM, Higgins J, Boucher CA. Effects of anti-anginal therapy on
`left ventricular systolic and diastolic performance: Comparison of the response to bepridil,
`diltiazem and propranolol. Amer J Cardiol 1992; 69:25D-30D.
`
`
`42. Zusman RM, Christensen DM, Higgins J, Boucher CA. Comparison of the cardiac and
`hemodynamic effects of lisinopril and atenolol in patients with hypertension: Therapeutic
`implications. J Cardiovasc Pharmacol 1992; 20:216-222.
`
`
`43. Zusman RM. Left ventricular hypertrophy and performance: Therapeutic options among
`the
`angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol 1992; 20(Supp
`10):S21-S28.
`
`
`44. Zusman RM, Higgins J, Christensen DM, Boucher CA. Bepridil improves left ventricular
`performance in patients with angina pectoris. J Cardiovasc Pharmacol, 1993; 22:474-480.
`
`
`45. Zusman RM, Hui K, Nussberger J, Christensen DM, Higgins J, Carlson WD, Schoenfeld D,
`Haber E. R-PEP-27, a potent inhibitor, decreases plasma angiotensin II and blood pressure
`in normal volunteers. Am J Hypertension 1994; 7:295-301.
`14
`
`
`
`CFAD Ex. 1027 (14 of 31)
`
`

`
`
`
`
`46. Zervos G, Zusman RM, Swindle LA, Alpert NM, Fischman AJ, Gewirtz H. Effect of
`nifedipine on myocardial blood flow and systolic function in humans with ischemic heart
`disease. Coronary Artery disease 1999; 10: 185-194.
`
`
`
`47. Tawakol A, Azi, K, Migrino R, Watkowska J, Zusman R, Alpert NM, Fischman AJ, and
`Gewirtz H, Effects of Sildenafil on Myocardial Blood Flow in Humans with Ischemic Heart
`Disease, Coronary Artery Disease 2005; 16:443-449.
`
`
`48. Wilens, T., Zusman, R., Hammerness, P., Podolski, A., Whitley, J., Spencer, T., Gignac, M.,
`and Biederman, J. An Open –Label Study of the Tolerability of Mixed Amphetamine Salts
`in Adults with Attention-Defici/Hyperactivity Disorder and Treated Primary Essential
`Hypertension. J Clin Psychiatry, 2006; 67: 696-702.
`
`
`49. Hammerness P, Zusman R, Systrom D, Surman C, Baggish A, Schillinger M, and Wilens T.
`A Pilot Cardiovascular Study of Lisdexamfetamine in Adults with Attention-
`Deficit/Hyperactivity Disorder (ADHD), World J Biological Psychiatry, 2012, ePub.
`
`50. Moore JO, Marshall M, Judge DC, Crocker BJ and Zusman RM. Technology-Supported
`Apprenticeship in the Management of Hypertension. Journal of Clinical Outcomes
`Management, 2014, in press.
`
`
`
`Clinical Communications (Peer-Reviewed)
`
`1.
`
`Cronin CM, Mitrano EA, Wilder RS, Harmon EP, Zusman RM. Comparative evaluation of
`the three commercially available transdermal nitroglycerin delivery systems. Drug
`Intelligence and Clinical Pharmacy 1987; 21:642-644.
`
`Zusman RM, Christensen D, Federman E, Kochar M, McCarron D, Proush J. Comparison
`of nifedipine and propranolol used in combination with diuretics for the treatment of
`hypertension.
`Am J Med 1987; 82(3B)37-41.
`
`Bolzano K, Arriaga J, Bernal R, Bernardes H, Calderon JL, Debruyn J, Dienstl F, Drayer J,
`Goodfriend TL, Gross W, Guthrie GP, Holwerda N, Klein W, Krakoff L, Liebau H, Oparil
`S, Reams GP, Reed WG, Safar M, Schubotz R, Seedat YK, Thind GS, Veriava Y, Wollam G,
`Woods JW, Zusman RM. The antihypertensive effect of lisinopril compared to atenolol in
`patients with mild to moderate hypertension. J Cardiol Pharmacol, Raven Press, New York,
`1987; 9(Suppl 3):S43-S47).
`
`Zachariah PK, Bonnet G, Chrysant SG, DeBacker G, Goldstein R, Herrera J, Lindner A,
`Materson BJ, Maxwell MH, McMahon FG, Merrill RH, Paton RR, Rapp AD, Roginsky MS,
`Seedat YK, Sime F, Vaicaitis JS, Weinberg MS, Zusman RM. Evaluation of
`antihypertensive efficacy of lisinopril compared to metoprolol in moderate to severe
`hypertension. J Cardiol Pharmacol, Raven Press, New York, 1987; 9(Suppl 3):S53-S58.
`
`15
`
`
`
`
`2.
`
`
`3.
`
`
`4.
`
`
`
`CFAD Ex. 1027 (15 of 31)
`
`

`
`
`
`
`6.
`
`
`
`7.
`
`
`8.
`
`
`9.
`
`5. Wolfson P, Abernethy D, DiPette D, Zusman RM. Diltiazem and captopril alone or in
`combination for treatment of mild to moderate hypertension. Am J Cardiol 1988; 62:103G-
`108G.
`
`Goldberg MR, Sushak MS, Rockhold FW, Thompson WL and the Pinacidil vs Prazosin
`Multicenter Investigator Group (Zusman RM). Vasodilator monotherapy in the treatment
`of hypertension: Comparative efficacy and safety of pinacidil, a potassium channel opener,
`and prazosin. Clin Pharm Therapeutics 1988; 44(1):78-92.
`
`Rockhold FW, Goldberg MR, Thompson WL and the Pinacidil-Prazosin and Pinacidil-
`Placebo Research Groups (Zusman RM). Beneficial effects of pinacidil on blood lipids:
`